2000
Gender differences in the initiation of injection drug use among young adults
Doherty M, Garfein R, Monterroso E, Latkin C, Vlahov D. Gender differences in the initiation of injection drug use among young adults. Journal Of Urban Health 2000, 77: 396-414. PMID: 10976613, PMCID: PMC3456045, DOI: 10.1007/bf02386749.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusInjection drug useHIV risk profilesDrug useRisk behaviorsRisk profileLow HIV prevalenceInjection drug usersMale sex partnersCommunity-based recruitmentPercentage of womenMale IDUsHIV prevalenceImmunodeficiency virusRisky injectionMost womenGender differencesDrug usersSex partnersInjection initiationYoung womenPatterns of initiationNumber of personsYoung adultsWomen
1997
Syphilis in injecting drug users: clues for high-risk sexual behaviour in female IDUs
Muga R, Roca J, Tor J, Pigem C, Rodriguez R, Egea J, Vlahov D, Muñoz A. Syphilis in injecting drug users: clues for high-risk sexual behaviour in female IDUs. International Journal Of STD & AIDS 1997, 8: 225-228. PMID: 9147154, DOI: 10.1258/0956462971919967.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusRapid plasma reagentEnzyme-linked immunosorbent assaySerologic syphilisDrug usersSex partnersHigh-risk sexual behaviorCross-sectional analysisGender-specific differencesMale IDUsHIV infectionImmunodeficiency virusFemale IDUsSexual transmissionTreponemal testsReactive samplesSyphilisSexual partnersWestern blotImmunosorbent assayIDUsPlasma reagentWomenSexual behaviorMen
1996
Differences in the Incidence of Hepatitis B and Human Immunodeficiency Virus Infections among Injecting Drug Users
Levine O, Vlahov D, Brookmeyer R, Cohn S, Nelson K. Differences in the Incidence of Hepatitis B and Human Immunodeficiency Virus Infections among Injecting Drug Users. The Journal Of Infectious Diseases 1996, 173: 579-583. PMID: 8627020, DOI: 10.1093/infdis/173.3.579.Peer-Reviewed Original ResearchConceptsHepatitis B virusHBV seroconversionOutcome measuresDrug usersHuman immunodeficiency virus type 1 (HIV-1) seroconversionIncident hepatitis B virusHuman immunodeficiency virus (HIV) infectionHIV seroconversion ratesHIV-seronegative IDUsSubsequent HIV seroconversionImmunodeficiency virus infectionInjecting Drug UsersSurrogate outcome measureImportant outcome measureNeedle exchange programsMale IDUsHIV seroconversionIncident HIVSeroconversion ratesHepatitis BHIV infectionFemale IDUsB virusVirus infectionSeroconversion
1993
Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users
Strickler H, Blanchard J, Vlahov D, Taylor E, Muñoz A, Nelson K, Margolick J. Elevated serum levels of neopterin but not β2-microglobulin in HIV-1-seronegative injecting drug users. AIDS 1993, 7: 361-368. PMID: 8471199, DOI: 10.1097/00002030-199303000-00009.Peer-Reviewed Original ResearchConceptsDrug useNeopterin levelsSerum levelsDrug usersSerum beta 2MBeta 2M levelsSerum beta 2M levelsMean neopterin levelsSerum neopterin levelsElevated serum levelsHIV-1 infectionCellular immune activationBeta 2MRisk factor variablesIntravenous Experience (ALIVE) studyM levelsMale IDUsSerum neopterinImmune activationProspective studyImmunocompetent cellsHIV-1Β2-microglobulinConsecutive daysNeopterin